Expert opinion on investigational drugs最新文献_第2页

How can we determine suitable combination immunotherapies for cancer by looking at the molecular targeting of each therapy? 我们如何通过观察每种疗法的分子靶向来确定适合的癌症联合免疫疗法？

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-09-01 Epub Date: 2026-08-20 DOI: 10.1080/13543784.2026.2718960

Nicole Sala, Giovanni Dalla Via, Giacomo De Micheli, Dario Trapani, Giuseppe Curigliano

引用次数: 0

HLD-0915: Could it be the breakthrough drug we need for metastatic prostate cancer? HLD-0915：它会成为治疗转移性前列腺癌的突破性药物吗？

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-09-01 Epub Date: 2026-08-29 DOI: 10.1080/13543784.2026.2724869

Jakob R Nypaver, Pedro C Barata

引用次数: 0

Telisotuzumab adizutecan for metastatic colorectal cancer: a c-MET-targeted antibody-drug conjugate with a topoisomerase inhibitor payload. Telisotuzumab adizutecan用于转移性结直肠癌：c- met靶向抗体-药物偶联物与拓扑异构酶抑制剂有效载荷。

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-09-01 Epub Date: 2026-08-19 DOI: 10.1080/13543784.2026.2717151

Yuki Matsubara, Akihito Kawazoe

{"title":"Telisotuzumab adizutecan for metastatic colorectal cancer: a c-MET-targeted antibody-drug conjugate with a topoisomerase inhibitor payload.","authors":"Yuki Matsubara, Akihito Kawazoe","doi":"10.1080/13543784.2026.2717151","DOIUrl":"10.1080/13543784.2026.2717151","url":null,"abstract":"Introduction: Metastatic colorectal cancer (mCRC) remains a disease of significant unmet need, particularly for patients with refractory disease and limited targeted treatment. However, c-MET protein overexpression, which has been associated with poor prognosis, represents an emerging therapeutic target. Telisotuzumab adizutecan (Temab-A) is a novel antibody-drug conjugate designed to deliver a potent topoisomerase 1 inhibitor payload to c-MET-expressing tumor cells.Areas covered: This review summarizes the pharmacology, clinical efficacy, and safety of Temab-A in mCRC. In a phase 1 study, 122 heavily pretreated patients with mCRC showed an objective response rate (ORR) of 15.6%; in an exploratory post-hoc subgroup (n = 25) with high c-MET expression treated at doses ≥2.4 mg/kg, ORR was 36.0%. In a phase 1 dose-optimization cohort (n = 30 at the recommended phase 2 dose), Temab-A plus bevacizumab showed an ORR of 30% and median progression-free survival of 6.8 months in an unselected population.Expert opinion: By exploiting c-MET surface expression rather than signaling dependency, Temab-A provided preliminary clinical activity across a broad population, including a clinically meaningful subgroup with c-MET overexpression. The ongoing phase 3 AndroMETa-CRC-560 trial will determine whether Temab-A plus bevacizumab can become a new therapeutic option for mCRC.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"667-674"},"PeriodicalIF":4.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148790140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigational interleukin 17A antagonists in the treatment of psoriatic arthritis. 白介素17A拮抗剂治疗银屑病关节炎的研究。

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-07-29 DOI: 10.1080/13543784.2026.2710840

Osariemen Osunbor, Jan René Nkeck, Adewale O Adebajo

{"title":"Investigational interleukin 17A antagonists in the treatment of psoriatic arthritis.","authors":"Osariemen Osunbor, Jan René Nkeck, Adewale O Adebajo","doi":"10.1080/13543784.2026.2710840","DOIUrl":"https://doi.org/10.1080/13543784.2026.2710840","url":null,"abstract":"Introduction: The global burden of psoriatic arthritis (PsA) is considerable, with major effects on both quality of life and life expectancy. Despite the existence of a diverse array of therapeutic interventions, approximately 40-50% of patients do not achieve the established therapeutic targets. Challenges related to tolerance, compliance, and therapeutic escape persist.Areas covered: This study is a comprehensive review of the current literature analyzing the central role of interleukin-17 (IL-17) in the pathogenesis of PsA and emphasizing current and investigational therapies for IL-17A blockade. A structured search was conducted in PubMed for the following terms investigational IL-17A antagonist and Psoriatic arthritis. We aimed for at least 100 research papers published within the last 20 years. In addition, clinical trials databases focusing on phase II - III IL-17A antagonists treatment in Psoriatic Arthritis were also reviewed.Expert opinion: The current stage of development and expansion of IL-17A antagonists encompasses the third generation of such molecules. This generation includes small, injectable molecules such as sonelokimab and izokibep; oral molecules; and bispecific monoclonal antibodies. This approach is purported to facilitate enhanced tissue diffusion, augmented efficacy in refractory forms, and simplified utilization. The future of PsA treatments is contingent upon the implementation of precision medicine, which leverages predictive biomarkers to personalize treatment from the moment of diagnosis. This could help control disease early and prevent progression, beyond the current Treat-to-Target strategy which mainly focuses on managing existing symptoms. The overarching objective is no longer to treat to target, but rather to treat to intercept, while ensuring the highest rate of control and tolerance for the patient.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis. 实验性新药TAP-1502开始临床研究治疗脂溢性皮炎。

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-07-01 Epub Date: 2026-07-05 DOI: 10.1080/13543784.2026.2698521

Burhan A Buttar, Sanat Subhash, Steven R Feldman

引用次数: 0

Investigational IL-17A antagonist in the treatment of psoriatic arthritis - a review. IL-17A拮抗剂治疗银屑病关节炎的研究综述

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-07-01 Epub Date: 2026-07-29 DOI: 10.1080/13543784.2026.2710840

Osariemen Osunbor, Jan René Nkeck, Adewale O Adebajo

{"title":"Investigational IL-17A antagonist in the treatment of psoriatic arthritis - a review.","authors":"Osariemen Osunbor, Jan René Nkeck, Adewale O Adebajo","doi":"10.1080/13543784.2026.2710840","DOIUrl":"10.1080/13543784.2026.2710840","url":null,"abstract":"Introduction: The global burden of psoriatic arthritis (PsA) is considerable, with major effects on both quality of life and life expectancy. Approximately 40-50% of patients do not achieve the established therapeutic targets. Challenges related to tolerance, compliance, and therapeutic escape persist.Areas covered: This study is a comprehensive review of the current literature analyzing the central role of interleukin-17 (IL-17) in the pathogenesis of PsA and emphasizing current and investigational therapies for IL-17A blockade.Expert opinion: The current stage of development and expansion of IL-17A antagonists encompasses the third generation of such molecules. This generation includes small, injectable molecules such as sonelokimab and izokibep; oral molecules; and bispecific monoclonal antibodies. This approach is purported to facilitate enhanced tissue diffusion, augmented efficacy in refractory forms, and simplified utilization. The future of PsA treatments is contingent upon the implementation of precision medicine. The overarching objective is no longer to treat to target, but rather to treat to intercept, while ensuring the highest rate of control and tolerance for the patient.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"581-589"},"PeriodicalIF":4.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148618894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights. 大麻素在成人镰状细胞病中的应用：治疗发展和临床见解。

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-07-01 Epub Date: 2026-06-25 DOI: 10.1080/13543784.2026.2689654

Galia Pollock, Charleen Jacobs-McFarlane, Jordan Bellis, Lydia Monk, Susanna Curtis

引用次数: 0

Vidofludimus calcium for the treatment of multiple sclerosis: development rationale, mechanism of action, and early trial data. 维多氟地莫钙治疗多发性硬化症：开发原理、作用机制和早期试验数据

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-07-01 Epub Date: 2026-07-21 DOI: 10.1080/13543784.2026.2705509

Matej Ondrus, Robert J Fox, Evelyn Peelen, Juliano Fonseca, Valentina Sciacca, Ines Sanchez-Gomez, Jacques Arend, Alexandra Herrmann, Maria Samcova, Christian Gege, Lesia Havrylova, Hella Kohlhof, Jason Tardio, Daniel Vitt, Andreas Muehler

{"title":"Vidofludimus calcium for the treatment of multiple sclerosis: development rationale, mechanism of action, and early trial data.","authors":"Matej Ondrus, Robert J Fox, Evelyn Peelen, Juliano Fonseca, Valentina Sciacca, Ines Sanchez-Gomez, Jacques Arend, Alexandra Herrmann, Maria Samcova, Christian Gege, Lesia Havrylova, Hella Kohlhof, Jason Tardio, Daniel Vitt, Andreas Muehler","doi":"10.1080/13543784.2026.2705509","DOIUrl":"10.1080/13543784.2026.2705509","url":null,"abstract":"Introduction: Multiple sclerosis (MS) is an autoimmune condition of the central nervous system associated with progressive disability. Safe and well tolerated treatments targeting both inflammatory and neurodegenerative processes are needed to address the spectrum of MS pathophysiology.Areas covered: Vidofludimus calcium is a potent, orally available direct activator of nuclear receptor-related 1 (Nurr1) protein and selective dihydroorotate dehydrogenase (DHODH) inhibitor. The article explores the chemistry, mechanisms of action, and pharmacokinetics of vidofludimus calcium. Furthermore, preliminary data from phase 2 trials are discussed.Expert opinion: The mechanism of action of vidofludimus calcium may allow targeting of focal neuroinflammation as well as chronic-compartmentalized inflammation and neurodegeneration. Treatment with vidofludimus calcium in patients with relapsing-remitting MS resulted in a statistically significant reduction of magnetic resonance imaging lesions in the phase 2 EMPhASIS trial. In CALLIPER, a phase 2 trial in patients with progressive MS, preliminary reports indicate consistent trends on signals related to disability progression across different disability outcomes and subpopulations. Completed studies indicate that vidofludimus calcium was generally well tolerated. In light of current unmet treatment needs, results from ongoing phase 3 trials are awaited with interest.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"565-579"},"PeriodicalIF":4.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ANGPTL3 gene editing with CRISPR-Cas9: early trial insights. 用CRISPR-Cas9编辑ANGPTL3基因：早期试验见解

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-07-01 Epub Date: 2026-04-13 DOI: 10.1080/13543784.2026.2656431

Xuan L Tang, Amanda J Hooper, John R Burnett

引用次数: 0

Targeting fatty acid synthase inhibitors for the treatment of acne vulgaris: what can we learn from early phase investigations. 靶向脂肪酸合成酶抑制剂治疗寻常性痤疮：我们可以从早期研究中学到什么？

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-07-01 Epub Date: 2026-07-13 DOI: 10.1080/13543784.2026.2701814

Dániel Törőcsik, Dóra Tiszai, Christos C Zouboulis

引用次数: 0